Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
artelo biosciences 在國際會議上展示了 ART27.13 針對癌症相關厭食症的第一階段數據，強調在三分之二的參與者中良好的耐受性以及體重的穩定或逆轉；CAReS 試驗的第二階段入組正在進行中
Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
artelo biosciences 在國際會議上展示了 ART27.13 針對癌症相關厭食症的第一階段數據，強調在三分之二的參與者中良好的耐受性以及體重的穩定或逆轉；CAReS 試驗的第二階段入組正在進行中
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。